Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WuXi PharmaTech Announces Third Quarter 2007 Results (China)

This article was originally published in PharmAsia News

Executive Summary

WuXi PharmaTech Inc. recently released encouraging financial results for the third quarter of 2007. The company is China's top provider of pharmaceutical and biotechnology research and development outsourcing services. The company's net revenues skyrocketed 77.8 percent from the same time last year to reach $34.0 million. Operating expenses also increased 38.1 percent to $8.5 million. Despite rising costs, WuXi also reported a gross profit increase of 76.4 percent to $16 million. Representatives for the company attribute its success in the third quarter to both existing and new revenue sources. Over this time, WuXi began operations at a new formulation development lab. They also broke ground on a drug safety evaluation center and began work at an animal testing facility designed to supplement safety testing until the new facility is completed. Already WuXi provides outsourcing services to 70 pharmaceutical companies, including nine out of ten of the leading drug producers in the world. (Click here for more - May Require Paid Subscription

You may also be interested in...

Finance Watch: Biopharma VC Explosion Extends To Tools, Services

Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.

Zimmer Biomet Buys Sternal Closure Company A&E Medical

The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.

Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts